Management of surgical procedures in patients with inherited F VII deficiency: six years of experience

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F14%3AE0104498" target="_blank" >RIV/00843989:_____/14:E0104498 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/14:A1501E0G

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Management of surgical procedures in patients with inherited F VII deficiency: six years of experience

Popis výsledku v původním jazyce

Inherited factor VII (FVII) deficiency is the most frequently observed rare bleeding disorder. The clinical symptoms are extremely variable, and patients may be asymptomatic or may present with life-threatening bleeding disorders. FVII activity (FVII: C)values of 10-15% are considered safe for maintenance of hemostasis, and replacement therapy is recommended for some types of surgical procedures. Twenty-three adult patients with FVII:C deficiency are followed-up in the Ostrava Haemophilia Treatment Centre. Eleven patients underwent a total of fourteen invasive procedures between 2008 and 2013. In terms of replacement therapy, nine patients received plasma-derived FVII and five patients received activated recombinant FVII. None of the patients had excessive blood loss during surgery, and there were no bleeding or other complications during post-operative treatment. In addition, there were no thromboembolic events related to the use of replacement therapy.

Název v anglickém jazyce

Management of surgical procedures in patients with inherited F VII deficiency: six years of experience

Popis výsledku anglicky

Inherited factor VII (FVII) deficiency is the most frequently observed rare bleeding disorder. The clinical symptoms are extremely variable, and patients may be asymptomatic or may present with life-threatening bleeding disorders. FVII activity (FVII: C)values of 10-15% are considered safe for maintenance of hemostasis, and replacement therapy is recommended for some types of surgical procedures. Twenty-three adult patients with FVII:C deficiency are followed-up in the Ostrava Haemophilia Treatment Centre. Eleven patients underwent a total of fourteen invasive procedures between 2008 and 2013. In terms of replacement therapy, nine patients received plasma-derived FVII and five patients received activated recombinant FVII. None of the patients had excessive blood loss during surgery, and there were no bleeding or other complications during post-operative treatment. In addition, there were no thromboembolic events related to the use of replacement therapy.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of blood disorders & transfusion

ISSN

2155-9864

e-ISSN

—

Svazek periodika

5

Číslo periodika v rámci svazku

n. 9

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

3

Strana od-do

"p. 239"

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—